Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for ADPT

Stock NameAdaptive Biotechnologies Corp
TickerADPT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS00650F1093
LEI549300ZTF7OT1FW66Q96

Show aggregate ADPT holdings

News associated with ADPT

ADPT Crosses Above Average Analyst Target
In recent trading, shares of Adaptive Biotechnologies Corp (Symbol: ADPT) have crossed above the average analyst 12-month target price of $13.25, changing hands for $13.49/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: dow - 2025-09-12 08:06:46
Analysts Set Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Price Target at $12.38
Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective […] - 2025-09-10 02:16:59
Adaptive Biotechnologies Reaches Analyst Target Price
In recent trading, shares of Adaptive Biotechnologies Corp (Symbol: ADPT) have crossed above the average analyst 12-month target price of $12.12, changing hands for $12.54/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: dow - 2025-08-08 08:23:12
Adaptive Biotechnologies (NASDAQ:ADPT) Given New $15.00 Price Target at TD Cowen
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) had its price target upped by stock analysts at TD Cowen from $13.00 to $15.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s target price would suggest a potential upside of 19.62% from the […] - 2025-08-08 03:02:57
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High Following Strong Earnings
Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $12.83 and last traded at $10.93, with a volume of 742398 shares traded. The stock had previously closed at $11.05. The company […] - 2025-08-08 02:19:02
Victory Capital Management Inc. Grows Stock Position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Victory Capital Management Inc. boosted its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 9,892.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,764,227 shares of the company’s stock after buying an additional 1,746,571 shares during the period. Victory Capital Management Inc.’s […] - 2025-07-24 04:53:21
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $10.57 Consensus PT from Brokerages
Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target […] - 2025-07-22 02:10:47
D.A. Davidson & CO. Has $682,000 Stock Holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
D.A. Davidson & CO. boosted its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 3.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 91,850 shares of the company’s stock after acquiring an additional 3,400 shares during the period. D.A. Davidson & CO.’s holdings […] - 2025-07-10 05:25:16
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $10.57 Average Target Price from Brokerages
Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target […] - 2025-06-27 02:10:57
Adaptive Biotechnologies Reaches Analyst Target Price
In recent trading, shares of Adaptive Biotechnologies Corp (Symbol: ADPT) have crossed above the average analyst 12-month target price of $11.62, changing hands for $11.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: dow - 2025-06-26 08:37:35
Adaptive Biotechnologies (NASDAQ:ADPT) Coverage Initiated at Craig Hallum
Equities research analysts at Craig Hallum assumed coverage on shares of Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. Craig Hallum’s price target would suggest a potential upside of 43.27% from […] - 2025-06-20 02:15:14
Brighton Jones LLC Has $166,000 Stock Position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Brighton Jones LLC decreased its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 8.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,318 shares of the company’s stock after selling 1,971 shares during the period. Brighton Jones […] - 2025-06-19 05:35:04
Rhumbline Advisers Acquires 7,322 Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Rhumbline Advisers raised its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 4.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 188,524 shares of the company’s stock after buying an additional 7,322 shares during the quarter. Rhumbline Advisers’ holdings in Adaptive […] - 2025-06-19 04:42:43
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) during the fourth quarter, Holdings Channel reports. The fund bought 118,593 shares of the company’s stock, valued at approximately $711,000. A number of other institutional investors also recently bought […] - 2025-06-11 04:38:55
Analysts Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Target Price at $9.83
Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year […] - 2025-06-02 02:50:50
Quantinno Capital Management LP Takes Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Quantinno Capital Management LP acquired a new stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 16,688 shares of the company’s stock, valued at approximately $100,000. A number of other […] - 2025-05-29 04:59:02
Deutsche Bank AG Grows Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Deutsche Bank AG boosted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 397.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 630,577 shares of the company’s stock after buying an additional 503,842 shares during the period. Deutsche Bank AG owned approximately […] - 2025-05-20 05:14:56
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Strong Trading Volume Following Analyst Upgrade
Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) saw unusually-strong trading volume on Monday after Morgan Stanley raised their price target on the stock from $7.00 to $9.00. Morgan Stanley currently has an equal weight rating on the stock. Approximately 1,380,969 shares traded hands during mid-day trading, a decline of 11% from the […] - 2025-05-07 02:21:01
Adaptive Biotechnologies Reaches Analyst Target Price
In recent trading, shares of Adaptive Biotechnologies Corp (Symbol: ADPT) have crossed above the average analyst 12-month target price of $9.86, changing hands for $10.03/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-05-06 08:20:53
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Adaptive Biotechnologies (NASDAQ:ADPT – Free Report) had its price target lifted by Morgan Stanley from $7.00 to $9.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts have also recently issued research reports about the stock. Scotiabank raised their price objective on […] - 2025-05-06 02:55:06
Analysts Predict 30% Upside For DWAS
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-02 08:52:50
Guggenheim Capital LLC Cuts Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Guggenheim Capital LLC trimmed its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 19.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,845 shares of the company’s stock after selling 10,093 shares during the quarter. Guggenheim Capital LLC’s […] - 2025-04-29 05:30:55
Prudential Financial Inc. Boosts Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Prudential Financial Inc. grew its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 3,290.8% during the 4th quarter, HoldingsChannel reports. The fund owned 481,965 shares of the company’s stock after purchasing an additional 467,751 shares during the period. Prudential Financial Inc.’s holdings in Adaptive Biotechnologies were worth $2,889,000 at the end of the […] - 2025-04-03 05:16:55
Is Bio-Techne Corporation Stock Underperforming the S&P 500?
Despite Bio-Techne Corporation’s underperformance relative to the S&P 500 over the past year, analysts maintain a bullish outlook on the stock’s prospects. - 2025-04-01 10:41:17
Analysts Anticipate 27% Upside For The Holdings of VB
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-01 08:04:16
Intech Investment Management LLC Purchases 11,865 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Intech Investment Management LLC increased its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 34.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 46,158 shares of the company’s stock after buying an additional 11,865 shares during the period. Intech Investment Management LLC’s holdings in Adaptive Biotechnologies were worth $277,000 as of its […] - 2025-03-27 06:22:57
Adaptive Biotechnologies (NASDAQ:ADPT) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies (NASDAQ:ADPT – Free Report) from a neutral rating to a buy rating in a research report released on Friday, Marketbeat.com reports. The Goldman Sachs Group currently has $9.00 price objective on the stock, up from their previous price objective of $8.00. ADPT has been the topic […] - 2025-03-24 04:28:56
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 6.1% on Insider Selling
Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report)’s stock price fell 6.1% on Thursday after an insider sold shares in the company. The company traded as low as $7.46 and last traded at $7.15. 41,184 shares changed hands during trading, a decline of 98% from the average session volume of 1,692,515 shares. The stock had […] - 2025-03-14 04:23:07
Caprock Group LLC Sells 2,500 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Caprock Group LLC lessened its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 19.4% during the 4th quarter, Holdings Channel reports. The firm owned 10,415 shares of the company’s stock after selling 2,500 shares during the quarter. Caprock Group LLC’s holdings in Adaptive Biotechnologies were worth $62,000 at the end of the most […] - 2025-02-08 06:49:17
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. increased its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Free Report) by 10.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 31,292 shares of the company’s stock after buying an additional 2,928 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Adaptive Biotechnologies […] - 2025-02-04 06:53:02

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ADPT holdings

DateNumber of ADPT Shares HeldBase Market Value of ADPT SharesLocal Market Value of ADPT SharesChange in ADPT Shares HeldChange in ADPT Base ValueCurrent Price per ADPT Share HeldPrevious Price per ADPT Share Held
2025-11-11 (Tuesday)97,721USD 1,419,886ADPT holding decreased by -17590USD 1,419,8860USD -17,590 USD 14.53 USD 14.71
2025-11-10 (Monday)97,721ADPT holding increased by 250USD 1,437,476ADPT holding decreased by -4120USD 1,437,476250USD -4,120 USD 14.71 USD 14.79
2025-11-07 (Friday)97,471USD 1,441,596ADPT holding decreased by -75053USD 1,441,5960USD -75,053 USD 14.79 USD 15.56
2025-11-06 (Thursday)97,471ADPT holding increased by 250USD 1,516,649ADPT holding decreased by -193468USD 1,516,649250USD -193,468 USD 15.56 USD 17.59
2025-11-05 (Wednesday)97,221USD 1,710,117ADPT holding increased by 65138USD 1,710,1170USD 65,138 USD 17.59 USD 16.92
2025-11-04 (Tuesday)97,221ADPT holding increased by 251USD 1,644,979ADPT holding decreased by -36481USD 1,644,979251USD -36,481 USD 16.92 USD 17.34
2025-11-03 (Monday)96,970USD 1,681,460ADPT holding decreased by -1939USD 1,681,4600USD -1,939 USD 17.34 USD 17.36
2025-10-31 (Friday)96,970USD 1,683,399ADPT holding increased by 43636USD 1,683,3990USD 43,636 USD 17.36 USD 16.91
2025-10-30 (Thursday)96,970ADPT holding increased by 1255USD 1,639,763ADPT holding increased by 31751USD 1,639,7631,255USD 31,751 USD 16.91 USD 16.8
2025-10-29 (Wednesday)95,715ADPT holding increased by 502USD 1,608,012ADPT holding decreased by -1088USD 1,608,012502USD -1,088 USD 16.8 USD 16.9
2025-10-28 (Tuesday)95,213USD 1,609,100ADPT holding decreased by -20947USD 1,609,1000USD -20,947 USD 16.9 USD 17.12
2025-10-27 (Monday)95,213USD 1,630,047ADPT holding decreased by -9521USD 1,630,0470USD -9,521 USD 17.12 USD 17.22
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ADPT by Blackrock for IE00BYXG2H39

Show aggregate share trades of ADPT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY25015.19014.350 14.434USD 3,609 9.38
2025-11-06BUY25017.38015.380 15.580USD 3,895 9.32
2025-11-04BUY25117.51016.510 16.610USD 4,169 9.24
2025-10-30BUY1,25517.36516.780 16.839USD 21,132 9.11
2025-10-29BUY50216.80017.400 17.340USD 8,705 9.07
2025-10-22SELL-1,00416.45017.240 17.161USD -17,230 8.86 Loss of -8,337 on sale
2025-10-20BUY50217.83017.870 17.866USD 8,969 8.76
2025-10-17BUY1,25416.30017.200 17.110USD 21,456 8.72
2025-10-15BUY2,00017.11017.140 17.137USD 34,274 8.67
2025-10-03BUY1,76414.38014.890 14.839USD 26,176 8.60
2025-10-02BUY25214.24014.740 14.690USD 3,702 8.57
2025-09-30BUY50414.96015.040 15.032USD 7,576 8.50
2025-09-26BUY50413.22013.250 13.247USD 6,676 8.45
2025-09-25BUY50413.13013.330 13.310USD 6,708 8.42
2025-09-24SELL-3,25912.82013.880 13.774USD -44,889 8.39 Loss of -17,537 on sale
2025-09-18BUY26113.77013.790 13.788USD 3,599 8.36
2025-09-17BUY78612.82013.330 13.279USD 10,437 8.34
2025-08-20SELL-1,04412.29512.630 12.597USD -13,151 8.23 Loss of -4,560 on sale
2025-07-30BUY1,04010.44010.710 10.683USD 11,110 8.09
2025-07-17SELL-52210.50010.865 10.828USD -5,652 7.94 Loss of -1,507 on sale
2025-07-11SELL-2,08811.82012.050 12.027USD -25,112 7.85 Loss of -8,723 on sale
2025-07-07BUY78311.74011.890 11.875USD 9,298 7.74
2025-07-02BUY14,35511.48011.805 11.773USD 168,994 7.68
2025-06-20BUY5,33610.38010.700 10.668USD 56,924 7.66
2025-06-11BUY48810.63010.870 10.846USD 5,293 7.52
2025-06-10BUY48810.46010.709 10.684USD 5,214 7.50
2025-06-04SELL-2449.98010.250 10.223USD -2,494 7.42 Loss of -685 on sale
2025-04-23BUY2457.3807.860 7.812USD 1,914 6.97
2025-04-10SELL-1,9527.7258.140 8.099USD -15,808 6.92 Loss of -2,295 on sale
2025-04-08SELL-2447.6658.490 8.407USD -2,051 6.90 Loss of -368 on sale
2025-04-07SELL-2447.7058.140 8.097USD -1,976 6.89 Loss of -295 on sale
2025-04-04SELL-1,2257.4707.620 7.605USD -9,316 6.88 Loss of -887 on sale
2025-04-01BUY1,0127.5207.630 7.619USD 7,710 6.86
2025-03-31SELL-7387.4307.680 7.655USD -5,649 6.85 Loss of -591 on sale
2025-03-21BUY3,3158.4008.660 8.634USD 28,622 6.74
2025-03-14SELL-3,7927.2807.450 7.433USD -28,186 6.69 Loss of -2,822 on sale
2025-03-07SELL-4707.3507.920 7.863USD -3,696 6.65 Loss of -572 on sale
2025-03-04SELL-2358.1208.300 8.282USD -1,946 6.58 Loss of -399 on sale
2025-02-25BUY4708.4208.518 8.508USD 3,999 6.44
2025-02-19SELL-2348.3708.665 8.635USD -2,021 6.30 Loss of -547 on sale
2025-02-13BUY7028.5208.560 8.556USD 6,006 6.13
2025-02-12BUY2347.5507.710 7.694USD 1,800 6.10
2025-02-11BUY9367.8007.920 7.908USD 7,402 6.07
2024-12-30SELL-11,6516.1106.230 6.218USD -72,446 5.37 Loss of -9,862 on sale
2024-11-18SELL-4,0204.6805.100 5.058USD -20,333 5.09 Profit of 144 on sale
2024-11-08SELL-2685.8206.330 6.279USD -1,683 4.98 Loss of -348 on sale
2024-10-21SELL-2724.5504.620 4.613USD -1,255 0.00 Loss of -1,255 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ADPT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19183,543565678,19627.1%
2025-09-18219,538100525,33441.8%
2025-09-17144,3060449,13632.1%
2025-09-16168,5151,364503,73233.5%
2025-09-15304,004190678,44444.8%
2025-09-12236,983345749,57231.6%
2025-09-11641,0574031,408,51345.5%
2025-09-10359,7760643,55055.9%
2025-09-09148,03739391,74137.8%
2025-09-08135,9080632,79621.5%
2025-09-05176,3150459,13738.4%
2025-09-04336,10719,884807,44741.6%
2025-09-03242,2980690,05735.1%
2025-09-02140,1590394,57535.5%
2025-08-29150,552518442,62634.0%
2025-08-28207,2862,242764,03927.1%
2025-08-27331,4892,189747,44844.3%
2025-08-26147,8620411,69635.9%
2025-08-25126,2260408,75730.9%
2025-08-22246,4368,428672,35236.7%
2025-08-21206,643670526,70439.2%
2025-08-20147,583112372,44139.6%
2025-08-19344,8486,507817,81842.2%
2025-08-18376,01416,0131,014,96737.0%
2025-08-15229,967300545,25342.2%
2025-08-14236,2820491,37948.1%
2025-08-13564,782350911,12662.0%
2025-08-12263,3205,500683,93538.5%
2025-08-11171,91310533,54332.2%
2025-08-08477,8286,8691,125,29942.5%
2025-08-07800,4672,5501,840,91643.5%
2025-08-061,284,9577762,185,98158.8%
2025-08-05705,0351,2691,231,43057.3%
2025-08-04336,437100496,26867.8%
2025-08-01292,345241437,56166.8%
2025-07-31304,4882,165561,19854.3%
2025-07-30251,3830426,51658.9%
2025-07-29162,282222284,02357.1%
2025-07-28161,484200312,64151.7%
2025-07-25288,6350521,20455.4%
2025-07-24326,3112,900539,82160.4%
2025-07-23285,721417458,30362.3%
2025-07-22382,4861,372596,49364.1%
2025-07-21391,6870570,02468.7%
2025-07-18290,4181,333454,66363.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.